[시장보고서]세계의 휴미라(Humira) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 유통채널별, 지역별, 부문 예측(2025-2030년)

세계의 휴미라(Humira) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 유통채널별, 지역별, 부문 예측(2025-2030년)

Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn´s Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1750864

리서치사 : Grand View Research, Inc.

발행일 : 2025년 05월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,641,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,094,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,998,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 휴미라 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 휴미라 시장 규모는 2030년 41억 1,000만 달러로, 예측 기간 중 CAGR은 -11.29%로 감소할 것으로 예측되고 있습니다. 질병의 세계 유병률 상승에 견인되어 시장은 계속 지속적인 수요를 경험하고 있습니다.

휴미라 시장 점유율이 낮아진 것은 바이오시밀러의 이용 가능성이 높아진 것이 주요 원인입니다. 바이오시밀러의 채용이 증가하고 환자의 접근이 확대되고 있습니다.

시장이 축소되고 있다고는 해도, 특히 헬스 케어 인프라가 정비되어 자가 면역 질환에 대한 인식이 높아지고 있는 신흥국 시장에 있어서는 큰 성장 기회가 남아 있습니다. 대형 및 구연산염이 없는 제제와 고농도 주사제와 같은 새로운 제제는 특히 건강 관리의 틀과 상환 지원이 충실한 지역에서 휴미라에 대한 지속적인 수요를 뒷받침하고 있습니다.

AbbVie와 Amgen, Sandoz, Teva 등 주요 바이오시밀러 제조업체를 포함한 제약 기업은 전략적 제휴, 제품 차별화, 라이프사이클 관리를 통해 진화하는 상황에 대응하고 있습니다.

Simlandi와 같은 호환성이 있는 바이오시밀러의 출시와 Evernorth의 자기부담 제로 프로그램과 같은 최근의 동향은 저렴한 가격으로의 액세스를 요구하는 움직임이 강해지고 있는 것을 부조로 하고 있습니다. 늘어나면서 휴미라 업계경쟁 구도은 점점 역동적이 되고 있습니다.

휴미라 시장 보고서 하이라이트

제품별로는 선발품이 시장을 석권해 2024년의 점유율은 87.0%에 이르렀습니다.
용도별로는 류마티스 관절염이 시장을 독점해, 2024년에는 20.5%의 점유율을 차지했습니다.
유통채널별로는 병원약국이 시장을 선도하여 2024년에는 41.0%의 점유율을 차지했습니다.
이 시장의 주요 기업으로는 AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Sandoz 등이 있습니다.
2024년 6월, Coherus BioSciences는 휴미라의 바이오 시밀러 인 YUSIMRY의 Hong Kong King-Friend Industrial Co. Ltd.에 대한 판매를 완료했음을 밝혔습니다. Hong Kong King-Friend Industrial Co. Ltd.에 현금 4,000만 달러로 매각했으며, 이 거래는 2024년 6월 26일에 완료되었습니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
시장 규모와 예측 동향 분석, 2018-2030년
북미
- 국가별, 2018-2030년
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
- AbbVie
- Alvotech
- Amgen Inc.
- Boehringer Ingelheim Pharmaceuticals Inc.
- Celltrion Inc.
- Coherus Biosciences, Inc
- Fresenius Kabi AG
- Fujiflim Kyowa Kiran Biologics Co.,Ltd.
- Pfizer Inc.
- Samsung Bioepis
- Sandoz Inc.

>JHS

영문 목차

영문목차

Humira Market Growth & Trends:

The global humira market size is projected to reach USD 4.11 billion by 2030, declining at a CAGR of -11.29% during the forecast period, according to a new report by Grand View Research, Inc. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira's market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira's proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.

Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth's zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

Humira Market Report Highlights:

Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.
Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.
Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira's key patents, which has opened the market to a broader range of adalimumab-based therapies.
In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Humira Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Humira Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Branded
- 4.4.1. Branded Market, 2018 - 2030 (USD Million)
4.5. Biosimilar
- 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Humira Market: Application Business Analysis

5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Rheumatoid Arthritis
- 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
5.5. Psoriatic Arthritis
- 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
5.6. Crohn's Disease
- 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
5.7. Ulcerative Colitis
- 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
5.8. Ankylosing Spondylitis
- 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
5.9. Others
- 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Humira Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Humira Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Framework
  - 7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Framework
  - 7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Framework
  - 7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Framework
  - 7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Framework
  - 7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Reimbursement Framework
  - 7.5.4.5. France Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Target Disease Prevalence
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Reimbursement Framework
  - 7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Target Disease Prevalence
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Reimbursement Framework
  - 7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Target Disease Prevalence
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Reimbursement Framework
  - 7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Target Disease Prevalence
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Reimbursement Framework
  - 7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Target Disease Prevalence
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Reimbursement Framework
  - 7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Framework
  - 7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Framework
  - 7.6.4.5. India Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Framework
  - 7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Target Disease Prevalence
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. Reimbursement Framework
  - 7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Target Disease Prevalence
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Reimbursement Framework
  - 7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Target Disease Prevalence
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Reimbursement Framework
  - 7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Target Disease Prevalence
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Reimbursement Framework
  - 7.7.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Target Disease Prevalence
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. Reimbursement Framework
  - 7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Target Disease Prevalence
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Reimbursement Framework
  - 7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Target Disease Prevalence
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. Reimbursement Framework
  - 7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Target Disease Prevalence
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Reimbursement Framework
  - 7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. AbbVie
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Alvotech
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Amgen Inc.
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Celltrion Inc.
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Coherus Biosciences, Inc
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Fresenius Kabi AG
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Pfizer Inc.
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Samsung Bioepis
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Sandoz Inc.
  - 8.5.11.1. Overview
  - 8.5.11.2. Financial Performance
  - 8.5.11.3. Product Benchmarking
  - 8.5.11.4. Strategic Initiatives

한글목차

세계의 휴미라 시장의 성장과 동향

휴미라 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 휴미라 시장의 변수, 동향, 범위

제4장 휴미라 시장 : 제품별, 비즈니스 분석

제5장 휴미라 시장 : 용도별, 비즈니스 분석

제6장 휴미라 시장 : 유통 채널별, 비즈니스 분석

제7장 휴미라 시장 : 지역별, 추정 및 동향 분석